Search

everythinglearnresearchcommunity

for

Search:↓

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Fractional lasers effectively treat alopecia areata, especially when combined with minoxidil or cortisol.

Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.

New therapies for alopecia areata show potential but need more research.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Exosomes from fat-derived stem cells can potentially improve hair growth and could be a new treatment for immune-related hair loss.

People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.

More people are seeing dermatologists for hair and scalp problems now than in the past.

People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.

Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.

Several treatments are effective for pigmentary disorders like vitiligo and melasma.

The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.

Activated PRP injections are effective in treating hair loss and improving hair density.

Platelet-rich plasma therapy is a safe and effective treatment for alopecia areata.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.

Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.

Misinformation about alopecia can lead to poor treatment, so it's important for healthcare professionals to correct myths.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.

Both DPCP alone and with PRP are effective and safe for treating severe alopecia areata.

ILC1-like cells can independently cause alopecia areata by affecting hair follicles.

Oral tofacitinib successfully treated total body hair loss in one patient.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.